

“Sarcoma 0-40” Initiative Call of Interest- RTICC Faculty

Understanding of and treatment for Sarcomas and mesenchymal tumors are major questions in cancer research and an unmet clinical need. To make a significant impact on sarcoma of children and young adults, the RTICC (Technion), joined forces with Case Comprehensive Cancer Center (CCCC) at Case Western Reserve University in Cleveland, and the Department of Pediatrics, School of Medicine at Indiana University, to establish an international multi-center consortium termed “Sarcoma 0-40”.

SARCOMA 0-40

Sarcoma 0-40 is dedicated to make a significant impact on advancing basic, translational and clinical research on sarcoma in young patients (0 to 40) through innovative, multidisciplinary and collaborative research of researchers from the above institutions.

We invite principal investigators from diverse fields including medicine, biology, chemistry, biomedical engineering, biotechnology, exact and materials science, chemical engineering and clinicians with interest in sarcoma to join this endeavor. By jointly deciding on lead projects “Sarcoma 0-40” will foster collaborations across disciplines, encouraging the exchange of ideas, resources, and expertise in this partnership.

The initiative will include collaborative research grants, conferences, student exchange programs and additional activities to be developed. Whether your research focus is basic science, technology and engineering, computation, or you are a clinician specializing on sarcoma, we are eager to have you on board with us!

Among the potential consortium research topics are (not limited to):

- **Sarcoma Biology**
The sarcoma cell and its microenvironment including the immune and nervous system, mechanobiology, model organisms, genetics and omics aimed at discovering sarcoma vulnerabilities.
- **Early Diagnosis**
Develop and validate new diagnostic technologies and techniques to detect early-stage sarcoma.
- **Drug Discovery and Delivery**
Develop in silico and functional screens for discovering novel drugs and their advancement towards clinical trials.
- **Technologies**
Facilitate cutting-edge technological solutions, including biomedical engineering, biotechnology, and materials science innovations, to enhance sarcoma research and treatment.
- **Computation**
Apply computational tools, including sarcoma bioinformatics, AI, and machine learning technologies, to analyze large datasets of patients' cohorts, to identify patterns, optimize treatment strategies, and predict patient outcomes.

Interested principal investigators and clinicians are encouraged to [click here](#) to fill out the interest form by 10/3/2025.

Our immediate goal is to identify interested researchers to join a 'kickoff' event in late spring 2025, where the scientific projects will be jointly decided by the consortium members.

This is a unique opportunity to:

- Collaborate with leading researchers and clinicians from the 3 centers.
- Contribute to groundbreaking research on sarcoma.
- Access shared resources, data, and state-of-the-art facilities.
- Translate basic research into clinical applications and patient care.
- Expand the professional opportunities for you and your lab members.

